ICI 215,001 hydrochloride
The active metabolite of ZD 7114 (Cat. No. 0930).
Sold with the permission of AstraZeneca UK Ltd.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 100 mM in DMSO|
Preparing Stock Solutions
The following data is based on the product molecular weight 397.86. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.51 mL||12.57 mL||25.13 mL|
|5 mM||0.5 mL||2.51 mL||5.03 mL|
|10 mM||0.25 mL||1.26 mL||2.51 mL|
|50 mM||0.05 mL||0.25 mL||0.5 mL|
References are publications that support the products' biological activity.
If you know of a relevant reference for ICI 215,001 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: ICI 215,001 hydrochloride, supplier, β3-adrenoceptor, b3-adrenoceptor, β3-adrenergic, b3-adrenergic, agonists, Receptors, ICI215001, hydrochloride, AstraZeneca, Adrenergic, Beta-3, Receptors, Adrenergic, Beta-3, Receptors, Tocris Bioscience
2 Citations for ICI 215,001 hydrochloride
Citations are publications that use Tocris products. Selected citations for ICI 215,001 hydrochloride include:
Littmann et al (2015) Recruitment of β-arrestin 1 and 2 to the β2-adrenoceptor: analysis of 65 ligands. PLoS One 355 183 PMID: 26306764
Suárez et al (2014) Oleoylethanolamide enhances β-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat. Dis Model Mech 7 129 PMID: 24159189
Do you know of a great paper that uses ICI 215,001 hydrochloride from Tocris? If so please let us know.
ICI 215,001 hydrochloride Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.